Improved synthesis and characterization of cholesteryl oleate-loaded cationic solid lipid nanoparticles with high transfection efficiency for gene therapy applications

dc.contributor.authorSuñé Pou, Marc
dc.contributor.authorLimeres, Maria J.
dc.contributor.authorNofrerias Roig, Isaac
dc.contributor.authorNardi Ricart, Anna
dc.contributor.authorPrieto-Sánchez, Silvia
dc.contributor.authorEl Yousfi, Younes
dc.contributor.authorPérez Lozano, Pilar
dc.contributor.authorGarcía Montoya, Encarna
dc.contributor.authorMiñarro Carmona, Montserrat
dc.contributor.authorTicó Grau, Josep R.
dc.contributor.authorHernández-Munain, Cristina
dc.contributor.authorSuñé, Carlos
dc.contributor.authorSuñé i Negre, Josep M. (Josep Maria)
dc.date.accessioned2020-07-21T09:18:02Z
dc.date.available2021-08-01T05:10:16Z
dc.date.issued2019-08-01
dc.date.updated2020-07-21T09:18:03Z
dc.description.abstractThe development of new nanoparticle formulations that are capable of high transfection efficiency without toxicity is essential to provide new tools for gene therapy. However, the issues of complex, poorly reproducible manufacturing methods, and low efficiencies during in vivo testing have prevented translation to the clinic. We have previously reported the use of cholesteryl oleate as a novel excipient for solid lipid nanoparticles (SLNs) for the development of highly efficient and nontoxic nucleic acid delivery carriers. Here, we performed an extensive characterization of this novel formulation to make the scale up under Good Manufacturing Practice (GMP) possible. We also describe the complete physicochemical and biological characterization of cholesteryl oleate-loaded SLNs to ensure the reproducibility of this formula and the preservation of its characteristics before and after the lyophilization process. We defined the best manufacturing method and studied the influence of some parameters on the obtained nanoparticles using the Quality by Design (ICH Q8) guideline to obtain cholesteryl oleate-loaded SLNs that remain stable during storage and guarantee in vitro nucleic acid delivery efficacy. Our results indicate that this improved formulation is suitable for gene therapy with the possibility of scale-up the manufacturing of nanoparticles under GMP conditions.
dc.format.extent9 p.
dc.format.mimetypeapplication/pdf
dc.identifier.idgrec694153
dc.identifier.issn0927-7765
dc.identifier.urihttps://hdl.handle.net/2445/169196
dc.language.isoeng
dc.publisherElsevier B.V.
dc.relation.isformatofVersió postprint del document publicat a: https://doi.org/10.1016/j.colsurfb.2019.04.037
dc.relation.ispartofColloids and Surfaces B-Biointerfaces, 2019, vol. 180, p. 159-167
dc.relation.urihttps://doi.org/10.1016/j.colsurfb.2019.04.037
dc.rightscc-by-nc-nd (c) Elsevier B.V., 2019
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/3.0/es
dc.sourceArticles publicats en revistes (Farmàcia, Tecnologia Farmacèutica i Fisicoquímica)
dc.subject.classificationNanopartícules
dc.subject.classificationLípids
dc.subject.classificationTeràpia genètica
dc.subject.otherNanoparticles
dc.subject.otherLipids
dc.subject.otherGene therapy
dc.titleImproved synthesis and characterization of cholesteryl oleate-loaded cationic solid lipid nanoparticles with high transfection efficiency for gene therapy applications
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:eu-repo/semantics/acceptedVersion

Fitxers

Paquet original

Mostrant 1 - 1 de 1
Carregant...
Miniatura
Nom:
694153.pdf
Mida:
747.29 KB
Format:
Adobe Portable Document Format